利妥昔单抗注射液辅助疗法对NMOSD患者神经功能及免疫功能的影响分析  

Effect of Adjuvant Therapy of Rituximab Injection on Neural Function and Immune Function in Patients with NMOSD

作　　者：郝静 赵卿 HAO Jing;ZHAO Qing(Department of Neurology,Ordos Central Hospital,Ordos 017000,China)

机构地区：[1]内蒙古自治区鄂尔多斯市中心医院神经内科,内蒙古鄂尔多斯017000

出　　处：《中国伤残医学》2024年第23期69-72,共4页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:探究利妥昔单抗(RTX)注射液辅助疗法对视神经脊髓炎谱系疾病(NMOSD)患者神经功能及免疫功能的影响。方法:选取2021年3月—2024年3月鄂尔多斯市中心医院收治的88例NMOSD患者为研究对象,按随机数字表法将其分为研究组与对照组,各44例。研究组采用RTX注射液辅助疗法治疗,对照组采用甲泼尼龙琥珀酸钠序贯醋酸泼尼松治疗。两组均治疗持续28d。对比两组治疗效果、免疫功能指标、神经功能指标、不良反应发生情况。结果:治疗后,研究组CD3+、CD4+、CD4+/CD8+均较对照组高,差异均有统计学意义(P<0.05)。治疗后,研究组中枢神经特异性蛋白、神经元特异性烯醇化酶、胶质纤维酸性蛋白均较对照组低,差异均有统计学意义(P<0.05)。研究组治疗总有效率为97.73%,高于对照组的86.36%,差异有统计学意义(P<0.05)。两组不良反应发生率分别为11.36%、0.09%,差异无统计学意义(P>0.05)。结论:在NMOSD患者治疗中采用RTX注射液辅助疗法可改善患者免疫功能及神经功能,用药安全性高,治疗效果良好。Objective:To investigate the effects of rituximab(RTX)injection adjuvant therapy on neurological and immune function in patients with neuromyelitis optica spectrum disorders(NMOSD).Methods:A total of 88 NMOSD patients admitted to Ordos Central Hospital from March 2021 to March 2024 were selected as the study objects,and were divided into a study group and a control group according to random number table method,with 44 cases in each group.The study group was treated with RTX injection adjuvant therapy,and the control group was treated with Methylprednisolone Sodium Succinate followed by Prednisone Acetate.The treatment lasted for 28 days in both groups.The therapeutic effect,immune function index,neurological function index and the occurrence of adverse reactions were compared between the two groups.Results:After treatment,CD3+,CD4+and CD4+/CD8+in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the central nerve specific protein,neuron specific enolase and glial fibrinous acidic protein in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total effective rate of the study group was 97.73%,which was higher than 86.36%of the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the two groups was 11.36%and 0.09%respectively,with no statistical significance(P>0.05).Conclusion:The adjuvant therapy of RTX injection in the treatment of NMOSD patients can improve the immune function and nervous function of patients with high drug safety and good therapeutic effect.

关 键 词：视神经脊髓炎谱系疾病 利妥昔单抗注射液 辅助疗法 神经功能损伤 免疫功能 

分 类 号：R744.5[医药卫生—神经病学与精神病学]